Abstract:Serum amyloid A1 (SAA1) is an acute-phase protein involved in acute or chronic hepatitis. Its function is still controversial. In addition, the effect of the expression of SAA1 and its molecular function on the progression in hepatocellular carcinoma (HCC) is still unclear.To demonstrate the expression of SAA1 and its effect on the prognosis in HCC and explain further the correlation of SAA1 and immunity pathways.SAA1 expression in HCC was conducted with The Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA-LIHC) in GEPIA tool, and the survival analysis based on the SAA1 expression level was achieved in the Kaplan-Meier portal. The high or low expression group was then drawn based on the median level of SAA1 expression. The correlation of SAA1 and the clinical features were conducted in the UALCAN web-based portal with TCGA-LIHC, including tumor grade, patient disease stage, and the TP53 mutation. The correlation analysis between SAA1 expression and TP53 mutation was subjected to the TCGA portal. The tumor purity score and the immune score were analyzed with CIBERSORT. The correlation of SAA1 expression and tumor-infiltrating lymphocytes was achieved in TISIDB web-based integrated repository portal for tumor-immune system interactions. GSE125336 dataset was used to test the SAA1 expression in the responsive or resistant group with anti-PD1 therapy. Gene set enrichment analysis was applied to evaluate the gene enrichment signaling pathway in HCC. The similar genes of SAA1 in HCC were identified in GEPIA, and the protein-protein interaction of SAA1 was conducted in the Metascape tool. The expression of C-X-C motif chemokine ligand 2, C-C motif chemokine ligand 23, and complement C5a receptor 1 was studied and overall survival analysis in HCC was conducted in GEPIA and Kaplan-Meier portal, respectively.SAA1 expression was decreased in HCC, and lower SAA1 expression predicted poorer overall survival, progression-free survival, and disease-specific survival. Furthermore, SAA1 expression was further decreased with increased tumor grade and patient disease stage. Also, SAA1 expression was further downregulated in patients with TP53 mutation compared with patients with wild type TP53. SAA1 expression was negatively correlated with the TP53 mutation. Lower SAA1 predicted poorer survival rate, especially in the patients with no hepatitis virus infection, other than those with hepatitis virus infection. Moreover, the SAA1 expression was negatively correlated with tumor purity. In contrast, SAA1 expression was positively correlated with the immune score in HCC, and the correlation analysis between SAA1 expression and tumor-infiltrating lymphocytes also showed a positive correlation in HCC. Decreased SAA1 was closely associated with the immune tolerance of HCC. C-X-C motif chemokine ligand 2 and C-C motif chemokine ligand 23 genes were identified as the hub genes associated with SAA1, which could also serve as favorable prognosis markers for HCC.SAA1 is downregulated in the liver tumor, and it is closely involved in the progression of HCC. Lower SAA1 expression indicates lower survival rate, especially for those patients without hepatitis virus infection. Lower SAA1 expression also suggests lower immune infiltrating cells, especially for those with immune cells exerting anti-tumor immune function. SAA1 expression is closely associated with the anti-tumor immune pathways.

High SAA1 Expression Predicts Advanced Tumors in Renal Cancer

Upregulation of Serine Metabolism Enzyme PSAT1 Predicts Poor Prognosis and Promotes Proliferation, Metastasis and Drug Resistance of Clear Cell Renal Cell Carcinoma.

SAA1 Has Potential as a Prognostic Biomarker Correlated with Cell Proliferation, Migration, and an Indicator for Immune Infiltration of Tumor Microenvironment in Clear Cell Renal Cell Carcinoma

Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma

High Expression of Stearoyl-CoA Desaturase 1 Predicts Poor Prognosis in Patients with Clear Cell Renal Cell Carcinoma

Novel Amino Acid Metabolism‐related Gene Signature to Predict Prognosis in Clear Cell Renal Cell Carcinoma

Low SAA4 gene expression is associated with advanced HCC stage and a poor prognosis

Expression of AOX1 Predicts Prognosis of Clear Cell Renal Cell Carcinoma

High Expression of SLC16A1 as a Biomarker to Predict Poor Prognosis of Urological Cancers

Low expression of SLC34A1 is associated with poor prognosis in clear cell renal cell carcinoma

SLC2A1 Plays a Significant Prognostic Role in Lung Adenocarcinoma and is Associated with Tumor Immunity Based on Bioinformatics Analysis.

Enhanced expression of caveolin-1 possesses diagnostic and prognostic value and promotes cell migration, invasion and sunitinib resistance in the clear cell renal cell carcinoma

ACAT1 and Metabolism-Related Pathways Are Essential for the Progression of Clear Cell Renal Cell Carcinoma (ccrcc), As Determined by Co-expression Network Analysis

Increased Expression of ALDH1A1 Protein is Associated with Poor Prognosis in Clear Cell Renal Cell Carcinoma

S100A11 is a potential prognostic marker for clear cell renal cell carcinoma

Comprehensive Profiling of Aberrant Prognostic Alternative Splicing Signatures in Clear Cell Renal Cell Carcinoma: a Retrospective Study Based on Large-Scale Sequencing Data

Pro-cancer role of CD276 as a novel biomarker for clear cell renal cell carcinoma

Prognostic Significance of Two Lipid Metabolism Enzymes, HADHA and ACAT2, in Clear Cell Renal Cell Carcinoma

SAA1 Expression as a Potential Prognostic Marker of the Tumor Microenvironment in Glioblastoma

Proteins S100A8 and S100A9 Are Potential Biomarkers for Renal Cell Carcinoma in the Early Stages: Results from a Proteomic Study Integrated with Bioinformatics Analysis.

Expression and Significance of Yes-associated Protein and Large Tumor Suppressor Gene 1 in Renal Clear Cell Carcinoma